Cedars-Sinai physicians and scientists will share the results of new research aimed at improving the treatment of digestive diseases during the international meeting of the American College of Gastroenterology (ACG). The clinical conference will take place Oct. 21-26 in Charlotte, North Carolina, and is available for virtual and in-person attendance.
A review of studies about the effect of food insecurity on digestive diseases found a dearth of information, even as diet can often be both a direct cause of and a solution for many gastrointestinal conditions.
Researchers at University of California San Diego School of Medicine describe a new approach that uses machine learning to hunt for disease targets and then predicts whether a drug is likely to receive FDA approval.
Miguel Regueiro, M.D., has been named chair of Cleveland Clinic’s Digestive Disease & Surgery Institute (DDSI).
In a randomized clinical trial published in the journal PAIN, researchers found participants with moderate to severe irritable bowel syndrome (IBS) who were knowingly treated with a pharmacologically inactive pill — referred to as an honest or open-label placebo — reported clinically meaningful improvements in their IBS symptoms.
The new guideline recommends is a positive diagnostic strategy involving a careful history, physical examination, and limited diagnostic testing, which can substantially shorten time to appropriate therapy and be more cost-effective for patients.
A new $6 million, 5-year grant from the National Institutes of Health extends funding for the Silvio O. Conte Cleveland Digestive Diseases Research Core Center (DDRCC), a cross-institutional collaboration of digestive disease investigators.